September 07, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: Intimation regarding publication of newspapers advertisement relating to rights issue of equity shares of Anondita Medicare Limited the "Company") ("Rights Issue")

Ref: Regulation 84 of Chapter III of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements), Regulations, 2018 ("SEBI ICDR Regulations") read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

SYMBOL: ANONDITA

ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to the provisions of Regulation 84 of Chapter III of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and in relation to the Rights Issue of the Company, please find enclosed herewith copies of the newspaper advertisements published today, i.e., September 07, 2026, inter alia, informing about the completion of dispatch of the Letter of Offer and Application Form in relation to the Rights Issue.

The aforesaid advertisements have been published in the following newspapers:

1. Financial Express – English Language Newspaper (All Editions)
2. Jansatta – Hindi Language Newspaper (All Editions)

The aforesaid information is also being hosted on the website of the Company at https://anonditamedicare.com/

We request you to take the above information on your records.

Thanking You.
Yours faithfully,

For and on behalf of
ANONDITA MEDICARE LIMITED

BHAWNA BISHT Digitally signed by BHAWNA BISHT
Date: 2026.09.07 16:28:08 +05'30'

Bhawna Bisht
Company Secretary and Compliance Officer
M. No. A70843



This advertisement is for information purpose only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell the securities. This is not an announcement for the offer document.

Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Our Company was originally incorporated as a public limited company under the name "Anondita Medicare Limited" under the provisions of the Companies Act, 2013, vide certificate of incorporation dated March 12, 2024, issued by the Registrar of Companies, Central Registration Centre, bearing Corporate Identification Number L22193DL2024PLC428183. Prior to incorporation, the business of our Company was carried on by our Promoter, Mr. Anupam Ghosh, as a sole proprietorship under the name "M/s Anondita Healthcare", the entire business of which, including all assets and liabilities, was transferred to our Company pursuant to a Business Transfer Agreement dated April 01, 2024. For details of changes in the name and registered office of our Company, see "General Information" on page 01.

Registered Office: Flat No. 704, Narmada Block, N6, Sector-D, Pocket-6, Vasant Kunj, New Delhi - 110070, India
Corporate Office: D-001, Sector 80, Noida, Gautam Buddha Nagar, Noida, Uttar Pradesh-201301
Telephone: 0120-4520300| **Contact Person:** Ms. Bhawna Bisht, Company Secretary and Compliance Officer
Email: info@anonditamedicare.com | **Website:** www.anonditamedicare.com | **CIN:** L22193DL2024PLC428183

PROMOTER OF OUR COMPANY: MR. ANUPAM GHOSH, MRS. SONIA GHOSH AND MR. RESHANT GHOSH

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF THE ANONDITA MEDICARE LIMITED (THE "COMPANY" OR "THE ISSUER") ONLY

ISSUE OF UP TO 9,58,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH, AT PAR, AT A PRICE OF ₹950 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING UP TO ₹9101.00 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 97 RIGHTS EQUITY SHARES FOR EVERY 1831 FULLY PAID-UP EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS, WEDNESDAY, SEPTEMBER 02, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 67.

Assuming full subscription. Subject to finalisation of the Basis of Allotment

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

ISSUE OPENS ON	LAST DATE FOR ON MARKET RENUNCIATION*	ISSUE CLOSES ON#
Wednesday, September 09, 2026	Friday, September 11, 2026	Tuesday, September 22, 2026

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.*
 # Our Board or a duly authorised committee thereof will have the right to extend the Issue period as it may determine from time to time, but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

Simple, Safe, Smart way of Application. -Make use of it.!!!

* Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check the section on ASBA below.

FACILITIES OF APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Master Circular and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA.

For details, see "Making of an Application through the ASBA process" on Page 69 of the Letter of Offer.

Please note that subject to SCSBs, complying with the requirement of SEBI Circular bearing reference number CIR/CFD/DIL/1/2013 dated January 02, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI-registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this issue and clear demarcated funds should be available in such account for such an application.

CREDIT OF RIGHT ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations, read with SEBI ICDR Master Circular, the credit of Right Entitlements and Allotment of Right Equity Shares shall be made in the dematerialised form only.

PLEASE NOTE THAT CREDIT OF RIGHT ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE THE INVESTORS TO THE RIGHT EQUITY SHARES AND THE INVESTORS HAVE TO SUBMIT AN APPLICATION FOR THE RIGHT EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE BY MAKING FULL PAYMENT TOWARDS SHARES APPLIED. FOR FURTHER DETAILS, PLEASE SEE THE 'TERMS OF THE ISSUE-PROCESS OF MAKING AN APPLICATION IN THE ISSUE' ON PAGE 69 OF THE LETTER OF OFFER.

PLEASE NOTE THAT THE RIGHT ENTITLEMENTS, IF NO APPLICATION IS MADE BY THE ELIGIBLE EQUITY SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE THE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL LAPSE AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE

Please note that our Company has opened a separate demat suspense Escrow Account (namely, "**ANONDITA MEDICARE LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT**" **('Demat Suspense Account')** and has credited the Right Entitlements on the basis of the Equity Shares (a) held by Eligible Equity Shareholders which are held in physical form as on Record Date, or (b) which are held in the Account of the Investor Education and Protection Fund **('IEPF')** authority; or (c) of the Eligible Equity Shareholders whose demat accounts are frozen or where the Equity Shares are lying in the unclaimed/suspense escrow account/ demat suspense account/ demat suspense account (including those pursuant to Regulation 39 of the SEBI (LODR) Regulations or details of which are unavailable with our Company or with the Registrar on the Record Date or where the Equity Shares have been kept in abeyance or where instructions have been issued for stopping issue or transfer or where the letter of confirmation lying in the escrow account; or (d) where credit of the Right Entitlements have returned/reversed/failed for any reasons; (e) where ownership is currently under dispute, including any court or regulatory proceedings or where any legal notices have been issued, if any or (f) such other cases where our Company is unable to credit Right Entitlements for any other reasons. Please note that our Company has credited the Right Entitlements to the Demat Suspense Account on the basis of information available with our Company and to serve the interest of the Eligible Equity Shareholders to provide them a reasonable opportunity to participate in the issue. The credit of the Right Entitlements to the Demat Suspense Account by our Company does not create any right in favour of the relevant Eligible Equity Shareholder for transfer of the Right Entitlement to their demat account or to receive any Equity Shares in the Issue.

With respect to the Right Entitlements credited to the Demat Suspense Account, the Eligible Equity Shareholders are requested to provide relevant details/documents as acceptable to our Company or the Registrar (such as applicable regulatory approvals, self-attested PAN and client master sheet of demat account, details/records confirming the legal and beneficial ownership of their respective Equity Shares, etc.) no later than two clear Working Days prior to the Issue Closing Date i.e., by Friday, September 18, 2026, to enable credit of their Right Entitlements by way of transfer from the Demat Suspense Account to their Demat Account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this Issue, and the communication shall serve as an Intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account, is active to facilitate the aforementioned transfer. In the event that the Eligible Equity Shareholders are not able to provide the relevant details to our Company or the Registrar by the end of the two clear Working Days prior to the Issue Closing Date, Right Entitlements credited to the Demat Suspense Account shall lapse and extinguish in due course and such Eligible Equity Shareholders shall not have any claim against our Company and our Company shall not be liable to any such Eligible Equity Shareholders in any form or manner.

COMPLETION OF DISPATCH OF ISSUE MATERIAL

The dispatch of the Application Form, Letter of Offer dated August 27, 2026, and Right Entitlement Letter ('Issue Material') has been completed on September 05, 2026 for dispatch through email and for dispatch through Speed Post (Non-Email), as confirmed by the RTA. In case of Eligible Equity Shareholders who have provided their valid Email address to our Company, the Issue Material has been sent to their e-mail address and in case where Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material as applicable has been physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS:

An Investor wishing to participate in the Issue through the ASBA facility is required to have an ASBA enabled bank account with SCSBs prior to making the application. Investors desiring to make an application in the Issue through the ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/electronic application through the Website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block such Application Money payable on the Application in their respective ASBA Accounts. Investors should ensure that they have correctly submitted the Application Form and have provided an authorization to the SCSB, via the electronic mode or blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application. For the list of Banks which have been notified by the SEBI to act SCSBs for the ASBA process, please refer to https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFp i=yes&intmId=34.

MAKING OF AN APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS, ON PLAIN PAPER UNDER ASBA PROCESS

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of the Application Form as detailed above. In such cases of non-receipt of the Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Company, Registrar or Stock Exchange. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that in terms of Regulation 78 of SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilise the Application Form for any purpose, including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including the joint holders, in the same order and as per the specimen recorder with his/her bank, must reach the office of the Designateed branch of the SCSB before the Issue Closing Date and should contain the following particulars: 1. Name of our Company, being Anondita Medicare Limited 2. Name and address of the Eligible Equity Shareholder, including joint holders (in the same order as per the specimen recorded with our Company or the Depository) 3. Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on the Record Date) DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the Officials appointed by the Courts, PAN of the Eligible Equity Shareholders and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue. 5. Number of Equity Shares held as on Record Date; 6. Allotment option - only dematerialised form. 7. Number of Right Equity Shares entitled to 8. Total number of Right Equity Shares applied for 9. Number of additional Right Equity Shares applied for, if any (applicable only if entire Right Entitlements have been applied for); 10. Total number of Right Equity Shares applied for; 11. Total amount paid at the rate Rs.10/- per Right Equity Share; 12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account, such as the account number, name, address and the branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders shall be deemed to have made the representations, warranties and agreements set forth in *'Restrictions on Purchases and Resales - Eligible Investors'* on Page 92 of Letter of Offer, and shall include the following:

I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act). Or any United States securities laws, and may not be offered, sold, resold, or otherwise transferred within the United States (including its territories and possessions thereof, any State of the United States and the District of Columbia)(the "United States"), except pursuant to an exemption from or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any State of the United States in 'offshore transactions" in reliance on Regulation S under the U.S. Securities Act ("Regulation S") to existing shareholders and located in jurisdictions where such offer and sale of the Right Equity Shares is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions. I/We understands that the issue is not and under no circumstances is to be construed as an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of be said Rights Equity Shares or Rights Entitlements in the United States. I/we confirm that I/We (a) am/are not in the United States and am/are eligible to subscribe the Rights Equity Shares under applicable securities laws, (b) am/are complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar to the Issue, nor any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar to the Issue or, any other person acting or acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction. I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorised or to any person to whom it is unlawful to make such offer, sale or invitation.

I/We satisfy, and each account for which I/we are acting satisfies (a) all suitability standards for investors in investments of the type subscribed for herein, imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/We acknowledge that the Company, its affiliates and other will rely upon the truth and accuracy of the foregoing representation and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, including cases where an Investor submits Application Forms along with a plain paper Application, such Application shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar and not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar (i.e www.skylinerta.com) and the Stock Exchange, i.e. www.nseindia.com).

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the investors' ASBA Accounts on or before the Issue Closing Date.

If the shareholder makes an application using the Application Form as well as plain paper, both the applications shall be liable to be rejected at the option of the Issuer.

OVERSEAS SHAREHOLDERS: The distribution of Issue Materials and issue of Rights Entitlements, as well as Rights Equity Shares to persons in certain jurisdictions outside India, may be restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Draft Letter of Offer, Letter of Offer, the Rights Entitlement Letter or Application Form may come or who receive Rights Entitlement and propose to renounce or apply for Rights Equity Shares in the issue are required to inform themselves about and observe such restrictions. For more details. See "Restrictions on Purchases and Resales" beginning on page 92 of the Letter of Offer. Our Company is undertaking this Issue on a rights basis to the Eligible Equity Shareholders and has dispatched the Application Form, the Rights Entitlement Letter, and other Issue material only to the email addresses of Eligible Equity Shareholders who have provided an Indian address to our Company. In case the Eligible Equity Shareholders have provided their valid e-mail address, the Issue material is sent only to their valid e-mail address and in case the Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material is dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Investors can also access the Letter of Offer and the Application Form from the websites of the Registrar to the Issue, our Company, and the NSE.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Equity Shares have not been and will not be registered under the U.S. Securities Act, or any U.S. State Securities Laws and may not be offered, sold, resold or otherwise transferred within the United Slates, except in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. State Securities laws. Accordingly, the Equity Shares and the Rights Entitlements referred to in the Letter of Offer are being offered and sold only outside the United States in "offshore transactions" in reliance on Regulation S to existing shareholders located in jurisdictions where such offer and sale of the Equity Shares and/or rights entitlements is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions, the offering to which the Letter Of Offer relates is not and under no circumstances is to be construed as, an offering of any Equity Shares or Rights Entitlements for sale in the United States or as a solicitation therein of an offer to buy or transfer any of the said securities.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled Application Form or a plain paper Application is Tuesday, September 22, 2026, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as, may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSB, on or before the Issue Closing Date or such date as maybe extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in the section entitled *"Terms of the Issue- Basis of Allotment"* on page 85 or the Letter of Offer.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5:00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

Please ensure that the Application Form and necessary details are filled in. In place of the Application number, Investors can mention the reference number of the e-mail received from the Registrar informing about their Rights Entitlement or the last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of the application number.

SPECIFIC INVESTORS: Our Company confirms that the Promoters' renunciation of their Rights Entitlements under this Issue is not being made in favour of any specific investor(s) under Regulation 77B of the SEBI ICDR Regulations, 2018. The Promoters are renouncing their entire Rights Entitlements in favour of the public at large, through the renunciation mechanism prescribed under the SEBI ICDR Regulations, in the manner set out in "Terms of the Issue" of the Letter of Offer. Accordingly, no specific investor(s) have been identified or disclosed in connection with this Issue.

LISTING: The existing Equity Shares of our Company are listed on National Stock Exchange of India Limited ("NSE"). Our Company has received "in-principle" approval from NSE for listing the Rights Equity Shares through its letter Ref. No. NSE/LIST/C/2026/0866 dated August 25, 2026. Our Company has made the necessary application to the Stock Exchange to obtain trading approval for Rights Entitlement as required under SEBI ICDR Master Circular.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the letter of offer. The Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer Clause of NSE'.

AVAILABILITY OF ISSUE MATERIALS: The credit of Rights Entitlement does not constitute an offer, invitation to offer or solicitation for participation in the Issue. whether directly or indirectly, and only dispatch of the Issue Material shall constitute an offer, invitation or solicitation for participation in the Issue in accordance with the terms of the Issue Material Further, receipt of the Issue Materials (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone in (i) the United States or (ii) any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorized or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, the Letter of Offer and any other Issue Materials must be treated as sent for information only and should not be acted upon for subscription to Rights Equity Shares and should not be copied or re-distributed, in part or in full. Accordingly, persons receiving a copy of the Issue Materials should not distribute or send the Issue Materials in or into any jurisdiction where to do so, would or might contravene local securities laws or regulations, or would subject our Company or its affiliates to any filing or registration requirement (other than in India). If Issue Material is received by any person in any such jurisdiction or the United States, they must not seek to subscribe to the Rights Equity Shares. For more details, please see 'Restrictions on Purchases and Resales' beginning on page 92 of the Letter of Offer.

The Application Form, the Rights Entitlement Letter and other Issue Material will be sent/dispatched only to the Eligible Equity Shareholders who have provided an Indian address to our Company. In case such Eligible Equity Shareholders have provided their valid e-mail address. The Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue Material will be sent only to the valid email address and in case such Eligible Equity Shareholders have not provided a valid e-mail address, then the Application Form, the Rights Entitlement Letter and other Issue Material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Further, the Letter of Offer will be sent/dispatched to the Eligible Equity Shareholders who have provided their Indian addresses and who have made a request in this regard.

Investors can access the Draft Letter of Offer, the Letter of Offer. and the Application Form (provided that the Eligible Equity Shareholders are eligible to subscribe to the Rights Equity Shares under applicable laws) on the websites of:

(i) our Company at www.anonditamedicare.com;

(ii) the Registrar at www.skylinerta.com

(iii) the Stock Exchange at www.nseindia.com.

To update the respective Indian addresses/e-mail addresses/phone or mobile numbers in the records maintained by the Registrar or by our Company, Eligible Equity Shareholders should visit www.skylinerta.com. Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e. www.skylinerta.com) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company at www.anonditamedicare.com. Further, our Company will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

For risk factors and other details, please refer to the Letter of Offer.

If you have queries or grievances in connection with the Rights Issue, you may contact the Registrar to the Issue at the details given below, with a copy to the Company Secretary and Compliance Officer at info@anonditamedicare.com.

REGISTRAR TO THE ISSUE

Skyline Financial Services Private Limited

D-153 A, 1st Floor, Okhla Industrial Area, Phase-I, New Delhi-110020
Tel: 011-40450193-197 **| E-mail: ipo@skylinerta.com | Website:** www.skylinerta.com
Contact Person: Mr Anuj Rana **| SEBI Reg No:** INR000003241

All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy of the SCSB, giving full details such as name, address of the Applicant, contact number(s), Email address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms or the plain paper application, as the case may be was submitted by the Investors along with a photocopy of the acknowledgement slip.

For **Anondita Medicare Limited**
On behalf of the Board of Directors
Sd/-
Bhawna Bisht
Company Secretary & Compliance Officer

Date: September 07, 2026
Place: New Delhi

This advertisement is for information purpose only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell the securities. This is not an announcement for the offer document.

Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Our Company was originally incorporated as a public limited company under the name "Anondita Medicare Limited" under the provisions of the Companies Act, 2013, vide certificate of incorporation dated March 12, 2024, issued by the Registrar of Companies, Central Registration Centre, bearing Corporate Identification Number L22193DL2024PLC428183. Prior to incorporation, the business of our Company was carried on by our Promoter, Mr. Anupam Ghosh, as a sole proprietorship under the name "M/s Anondita Healthcare", the entire business of which, including all assets and liabilities, was transferred to our Company pursuant to a Business Transfer Agreement dated April 01, 2024. For details of changes in the name and registered office of our Company, see "General Information" on page 01.

Registered Office: Flat No. 704, Narmada Block, N6, Sector-D, Pocket-6, Vasant Kunj, New Delhi - 110070, India
Corporate Office: D-001, Sector 80, Noida, Gautam Buddha Nagar, Noida, Uttar Pradesh-201301
Telephone: 0120-4520300| **Contact Person:** Ms. Bhawna Bisht, Company Secretary and Compliance Officer
Email: info@anonditamedicare.com | **Website:** www.anonditamedicare.com | **CIN:** L22193DL2024PLC428183

PROMOTER OF OUR COMPANY: MR. ANUPAM GHOSH, MRS. SONIA GHOSH AND MR. RESHANT GHOSH

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF THE ANONDITA MEDICARE LIMITED (THE "COMPANY" OR "THE ISSUER") ONLY

ISSUE OF UP TO 9,58,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH, AT PAR, AT A PRICE OF ₹950 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING UP TO ₹9101.00 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 97 RIGHTS EQUITY SHARES FOR EVERY 1831 FULLY PAID-UP EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS, WEDNESDAY, SEPTEMBER 02, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 67.

Assuming full subscription. Subject to finalisation of the Basis of Allotment

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

ISSUE OPENS ON	LAST DATE FOR ON MARKET RENUNCIATION*	ISSUE CLOSES ON#
Wednesday, September 09, 2026	Friday, September 11, 2026	Tuesday, September 22, 2026

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.*
 # Our Board or a duly authorised committee thereof will have the right to extend the Issue period as it may determine from time to time, but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*	Simple, Safe, Smart way of Application. -Make use of it.!!!	* Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check the section on ASBA below.

FACILITIES OF APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Master Circular and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA.

For details, see "Making of an Application through the ASBA process" on Page 69 of the Letter of Offer.

Please note that subject to SCSBs, complying with the requirement of SEBI Circular bearing reference number CIR/CFD/DIL/1/2013 dated January 02, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI-registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this issue and clear demarcated funds should be available in such account for such an application.

CREDIT OF RIGHT ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations, read with SEBI ICDR Master Circular, the credit of Right Entitlements and Allotment of Right Equity Shares shall be made in the dematerialised form only.

PLEASE NOTE THAT CREDIT OF RIGHT ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE THE INVESTORS TO THE RIGHT EQUITY SHARES AND THE INVESTORS HAVE TO SUBMIT AN APPLICATION FOR THE RIGHT EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE BY MAKING FULL PAYMENT TOWARDS SHARES APPLIED. FOR FURTHER DETAILS, PLEASE SEE THE 'TERMS OF THE ISSUE-PROCESS OF MAKING AN APPLICATION IN THE ISSUE' ON PAGE 69 OF THE LETTER OF OFFER.

PLEASE NOTE THAT THE RIGHT ENTITLEMENTS, IF NO APPLICATION IS MADE BY THE ELIGIBLE EQUITY SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE THE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL LAPSE AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE

Please note that our Company has opened a separate demat suspense Escrow Account (namely, "**ANONDITA MEDICARE LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT**" **('Demat Suspense Account')** and has credited the Right Entitlements on the basis of the Equity Shares (a) held by Eligible Equity Shareholders which are held in physical form as on Record Date, or (b) which are held in the Account of the Investor Education and Protection Fund **('IEPF')** authority; or (c) of the Eligible Equity Shareholders whose demat accounts are frozen or where the Equity Shares are lying in the unclaimed/suspense escrow account/ demat suspense account/ demat suspense account (including those pursuant to Regulation 39 of the SEBI (LODR) Regulations or details of which are unavailable with our Company or with the Registrar on the Record Date or where the Equity Shares have been kept in abeyance or where instructions have been issued for stopping issue or transfer or where the letter of confirmation lying in the escrow account; or (d) where credit of the Right Entitlements have returned/reversed/failed for any reasons; (e) where ownership is currently under dispute, including any court or regulatory proceedings or where any legal notices have been issued, if any or (f) such other cases where our Company is unable to credit Right Entitlements for any other reasons. Please note that our Company has credited the Right Entitlements to the Demat Suspense Account on the basis of information available with our Company and to serve the interest of the Eligible Equity Shareholders to provide them a reasonable opportunity to participate in the issue. The credit of the Right Entitlements to the Demat Suspense Account by our Company does not create any right in favour of the relevant Eligible Equity Shareholder for transfer of the Right Entitlement to their demat account or to receive any Equity Shares in the Issue.

With respect to the Right Entitlements credited to the Demat Suspense Account, the Eligible Equity Shareholders are requested to provide relevant details/documents as acceptable to our Company or the Registrar (such as applicable regulatory approvals, self-attested PAN and client master sheet of demat account, details/records confirming the legal and beneficial ownership of their respective Equity Shares, etc.) no later than two clear Working Days prior to the Issue Closing Date i.e., by Friday, September 18, 2026, to enable credit of their Right Entitlements by way of transfer from the Demat Suspense Account to their Demat Account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this Issue, and the communication shall serve as an Intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account, is active to facilitate the aforementioned transfer. In the event that the Eligible Equity Shareholders are not able to provide the relevant details to our Company or the Registrar by the end of the two clear Working Days prior to the Issue Closing Date, Right Entitlements credited to the Demat Suspense Account shall lapse and extinguish in due course and such Eligible Equity Shareholders shall not have any claim against our Company and our Company shall not be liable to any such Eligible Equity Shareholders in any form or manner.

COMPLETION OF DISPATCH OF ISSUE MATERIAL

The dispatch of the Application Form, Letter of Offer dated August 27, 2026, and Right Entitlement Letter ('Issue Material') has been completed on September 05, 2026 for dispatch through email and for dispatch through Speed Post (Non-Email), as confirmed by the RTA. In case of Eligible Equity Shareholders who have provided their valid Email address to our Company, the Issue Material has been sent to their e-mail address and in case where Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material as applicable has been physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS:

An Investor wishing to participate in the Issue through the ASBA facility is required to have an ASBA enabled bank account with SCSBs prior to making the application. Investors desiring to make an application in the Issue through the ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/electronic application through the Website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block such Application Money payable on the Application in their respective ASBA Accounts. Investors should ensure that they have correctly submitted the Application Form and have provided an authorization to the SCSB, via the electronic mode or blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application. For the list of Banks which have been notified by the SEBI to act SCSBs for the ASBA process, please refer to https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFp i=yes&intmId=34.

MAKING OF AN APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS, ON PLAIN PAPER UNDER ASBA PROCESS

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of the Application Form as detailed above. In such cases of non-receipt of the Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Company, Registrar or Stock Exchange. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that in terms of Regulation 78 of SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilise the Application Form for any purpose, including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including the joint holders, in the same order and as per the specimen recorder with his/her bank, must reach the office of the Designateed branch of the SCSB before the Issue Closing Date and should contain the following particulars: 1. Name of our Company, being Anondita Medicare Limited 2. Name and address of the Eligible Equity Shareholder, including joint holders (in the same order as per the specimen recorded with our Company or the Depository) 3. Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on the Record Date) DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the Officials appointed by the Courts, PAN of the Eligible Equity Shareholders and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue. 5. Number of Equity Shares held as on Record Date; 6. Allotment option - only dematerialised form. 7. Number of Right Equity Shares entitled to 8. Total number of Right Equity Shares applied for 9. Number of additional Right Equity Shares applied for, if any (applicable only if entire Right Entitlements have been applied for); 10. Total number of Right Equity Shares applied for; 11. Total amount paid at the rate Rs.10/- per Right Equity Share; 12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account, such as the account number, name, address and the branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders shall be deemed to have made the representations, warranties and agreements set forth in *'Restrictions on Purchases and Resales - Eligible Investors'* on Page 92 of Letter of Offer, and shall include the following:

I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act). Or any United States securities laws, and may not be offered, sold, resold, or otherwise transferred within the United States (including its territories and possessions thereof, any State of the United States and the District of Columbia)(the "United States"), except pursuant to an exemption from or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any State of the United States in 'offshore transactions" in reliance on Regulation S under the U.S. Securities Act ("Regulation S") to existing shareholders and located in jurisdictions where such offer and sale of the Right Equity Shares is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions. I/We understands that the issue is not and under no circumstances is to be construed as an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of be said Rights Equity Shares or Rights Entitlements in the United States. I/we confirm that I/We (a) am/are not in the United States and am/are eligible to subscribe the Rights Equity Shares under applicable securities laws, (b) am/are complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar to the Issue, nor any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar to the Issue or, any other person acting or acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction. I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorised or to any person to whom it is unlawful to make such offer, sale or invitation.

I/We satisfy, and each account for which I/we are acting satisfies (a) all suitability standards for investors in investments of the type subscribed for herein, imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/We acknowledge that the Company, its affiliates and other will rely upon the truth and accuracy of the foregoing representation and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, including cases where an Investor submits Application Forms along with a plain paper Application, such Application shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar and not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar (i.e www.skylinerta.com) and the Stock Exchange, i.e. www.nseindia.com).

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the investors' ASBA Accounts on or before the Issue Closing Date.

If the shareholder makes an application using the Application Form as well as plain paper, both the applications shall be liable to be rejected at the option of the Issuer.

OVERSEAS SHAREHOLDERS: The distribution of Issue Materials and issue of Rights Entitlements, as well as Rights Equity Shares to persons in certain jurisdictions outside India, may be restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Draft Letter of Offer, Letter of Offer, the Rights Entitlement Letter or Application Form may come or who receive Rights Entitlement and propose to renounce or apply for Rights Equity Shares in the issue are required to inform themselves about and observe such restrictions. For more details. See "Restrictions on Purchases and Resales" beginning on page 92 of the Letter of Offer. Our Company is undertaking this Issue on a rights basis to the Eligible Equity Shareholders and has dispatched the Application Form, the Rights Entitlement Letter, and other Issue material only to the email addresses of Eligible Equity Shareholders who have provided an Indian address to our Company. In case the Eligible Equity Shareholders have provided their valid e-mail address, the Issue material is sent only to their valid e-mail address and in case the Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material is dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Investors can also access the Letter of Offer and the Application Form from the websites of the Registrar to the Issue, our Company, and the NSE.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Equity Shares have not been and will not be registered under the U.S. Securities Act, or any U.S. State Securities Laws and may not be offered, sold, resold or otherwise transferred within the United Slates, except in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. State Securities laws. Accordingly, the Equity Shares and the Rights Entitlements referred to in the Letter of Offer are being offered and sold only outside the United States in "offshore transactions" in reliance on Regulation S to existing shareholders located in jurisdictions where such offer and sale of the Equity Shares and/or rights entitlements is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions, the offering to which the Letter Of Offer relates is not and under no circumstances is to be construed as, an offering of any Equity Shares or Rights Entitlements for sale in the United States or as a solicitation therein of an offer to buy or transfer any of the said securities.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled Application Form or a plain paper Application is Tuesday, September 22, 2026, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as, may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSB, on or before the Issue Closing Date or such date as maybe extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in the section entitled *"Terms of the Issue- Basis of Allotment"* on page 85 or the Letter of Offer.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5:00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

Please ensure that the Application Form and necessary details are filled in. In place of the Application number, Investors can mention the reference number of the e-mail received from the Registrar informing about their Rights Entitlement or the last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of the application number.

SPECIFIC INVESTORS: Our Company confirms that the Promoters' renunciation of their Rights Entitlements under this Issue is not being made in favour of any specific investor(s) under Regulation 77B of the SEBI ICDR Regulations, 2018. The Promoters are renouncing their entire Rights Entitlements in favour of the public at large, through the renunciation mechanism prescribed under the SEBI ICDR Regulations, in the manner set out in "Terms of the Issue" of the Letter of Offer. Accordingly, no specific investor(s) have been identified or disclosed in connection with this Issue.

LISTING: The existing Equity Shares of our Company are listed on National Stock Exchange of India Limited ("NSE"). Our Company has received "in-principle" approval from NSE for listing the Rights Equity Shares through its letter Ref. No. NSE/LIST/C/2026/0866 dated August 25, 2026. Our Company has made the necessary application to the Stock Exchange to obtain trading approval for Rights Entitlement as required under SEBI ICDR Master Circular.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the letter of offer. The Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer Clause of NSE'.

AVAILABILITY OF ISSUE MATERIALS: The credit of Rights Entitlement does not constitute an offer, invitation to offer or solicitation for participation in the Issue. whether directly or indirectly, and only dispatch of the Issue Material shall constitute an offer, invitation or solicitation for participation in the Issue in accordance with the terms of the Issue Material Further, receipt of the Issue Materials (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone in (i) the United States or (ii) any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorized or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, the Letter of Offer and any other Issue Materials must be treated as sent for information only and should not be acted upon for subscription to Rights Equity Shares and should not be copied or re-distributed, in part or in full. Accordingly. persons receiving a copy of the Issue Materials should not distribute or send the Issue Materials in or into any jurisdiction where to do so, would or might contravene local securities laws or regulations, or would subject our Company or its affiliates to any filing or registration requirement (other than in India). If Issue Material is received by any person in any such jurisdiction or the United States, they must not seek to subscribe to the Rights Equity Shares. For more details, please see 'Restrictions on Purchases and Resales' beginning on page 92 of the Letter of Offer.

The Application Form, the Rights Entitlement Letter and other Issue Material will be sent/dispatched only to the Eligible Equity Shareholders who have provided an Indian address to our Company. In case such Eligible Equity Shareholders have provided their valid e-mail address. The Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue Material will be sent only to the valid email address and in case such Eligible Equity Shareholders have not provided a valid e-mail address, then the Application Form, the Rights Entitlement Letter and other Issue Material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Further, the Letter of Offer will be sent/dispatched to the Eligible Equity Shareholders who have provided their Indian addresses and who have made a request in this regard.

Investors can access the Draft Letter of Offer, the Letter of Offer. and the Application Form (provided that the Eligible Equity Shareholders are eligible to subscribe to the Rights Equity Shares under applicable laws) on the websites of:

(i) our Company at www.anonditamedicare.com;

(ii) the Registrar at www.skylinerta.com

(iii) the Stock Exchange at www.nseindia.com.

To update the respective Indian addresses/e-mail addresses/phone or mobile numbers in the records maintained by the Registrar or by our Company, Eligible Equity Shareholders should visit www.skylinerta.com. Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e. www.skylinerta.com) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company at www.anonditamedicare.com. Further, our Company will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

For risk factors and other details, please refer to the Letter of Offer.

If you have queries or grievances in connection with the Rights Issue, you may contact the Registrar to the Issue at the details given below, with a copy to the Company Secretary and Compliance Officer at info@anonditamedicare.com.

REGISTRAR TO THE ISSUE

Skyline Financial Services Pvt. Ltd.

Skyline Financial Services Private Limited
D-153 A, 1st Floor, Okhla Industrial Area, Phase-I, New Delhi-110020
Tel: 011-40450193-197 **| E-mail: ipo@skylinerta.com | Website:** www.skylinerta.com
Contact Person: Mr Anuj Rana **| SEBI Reg No:** INR000003241

All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy of the SCSB, giving full details such as name, address of the Applicant, contact number(s), Email address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms or the plain paper application, as the case may be was submitted by the Investors along with a photocopy of the acknowledgement slip.

For **Anondita Medicare Limited**
On behalf of the Board of Directors
Sd/-
Bhawna Bisht
Company Secretary & Compliance Officer

Date: September 07, 2026
Place: New Delhi